Corneal Biomechanics and Visual Field Progression in Eyes with Seemingly Well-Controlled Intraocular Pressure
Overview
Authors
Affiliations
Purpose: To investigate the incidence and risk factors for glaucomatous visual field progression in eyes with well-controlled intraocular pressure (IOP).
Design: Prospective cohort.
Participants: A total of 460 eyes of 334 patients with glaucoma under treatment.
Methods: Study subjects had a mean follow-up of 4.3±0.8 years. Patients were classified as well controlled if all IOP measurements were less than 18 mmHg. Rates of visual field progression were calculated using ordinary least-squares linear regression of standard automated perimetry (SAP) mean deviation (MD) values over time. Progression was defined as a significantly negative MD slope (alpha = 0.05).
Main Outcome Measures: Rates of SAP MD change; mean and peak IOP, and IOP fluctuation; and corneal biomechanics: corneal hysteresis (CH), central corneal thickness (CCT), and corneal index.
Results: Of the 179 eyes with well-controlled IOP, 42 (23.5%) demonstrated visual field progression. There was no significant difference between progressing and stable patients in baseline MD (-6.4±7.1 decibels [dB] vs. -6.0±6.2 dB; P = 0.346), mean IOP (11.7±2.0 mmHg vs. 12.1±2.3 mmHg; P = 0.405), IOP fluctuation (1.6±0.6 mmHg vs. 1.6±0.5 mmHg; P = 0.402), or peak IOP (14.3±1.9 mmHg vs. 14.6±2.1 mmHg; P = 0.926). Progressing eyes had significantly lower CH (8.6±1.3 mmHg vs. 9.4±1.6 mmHg; P = 0.014) and thinner CCT (515.1±33.1 μm vs. 531.1±42.4 μm; P = 0.018, respectively) compared with stable eyes. In the multivariate analysis, a 1 standard deviation lower corneal index, a summation of normalized versions of CH and CCT, resulted in a 68% higher risk of progression (odds ratio, 1.68; 95% confidence interval, 1.08-2.62; P = 0.021).
Conclusions: Approximately one-quarter of eyes with well-controlled IOP may show visual field progression over time. Thin cornea and low CH are main risk factors.
Central visual field in glaucoma: An updated review.
Du K, Kamalipour A, Moghimi S Taiwan J Ophthalmol. 2024; 14(3):360-370.
PMID: 39430344 PMC: 11488810. DOI: 10.4103/tjo.TJO-D-24-00042.
Oxylipins in Aqueous Humor of Primary Open-Angle Glaucoma Patients.
Xu J, Zhou K, Fu C, Chen C, Sun Y, Wen X Biomolecules. 2024; 14(9).
PMID: 39334893 PMC: 11430124. DOI: 10.3390/biom14091127.
Swaminathan S, Medeiros F, Gedde S Am J Ophthalmol. 2024; 267:172-181.
PMID: 38971319 PMC: 11486566. DOI: 10.1016/j.ajo.2024.06.024.
Valsecchi N, Roda M, Febbraro S, Trolli E, Palandri G, Giannini G Int Ophthalmol. 2024; 44(1):1.
PMID: 38315313 PMC: 10844352. DOI: 10.1007/s10792-024-02922-3.
Macedo M, Hatanaka M, Barboza W, Mingione G, Ambrosio Jr R, Susanna Jr R Sci Rep. 2023; 13(1):17864.
PMID: 37857798 PMC: 10587345. DOI: 10.1038/s41598-023-45165-5.